Toggle navigation
Home
Search
Services
Blog
Contact
About
Development of Heparin Antagonist for Clinical Use
Harris, Robert B.
Commonwealth Biotechnologies, Inc., Richmond, VA, United States
Search 280 grants from Robert Harris
Search grants from Commonwealth Biotechnologies, Inc.
Share this grant:
:
:
Abstract
Funding
Institution
Related projects
Comments
Recent in Grantomics:
Your institution
vs. funders. Who wins?
Read more...
How should you pick the next fundable research topic?
Read more...
Recently viewed grants:
Post-transcriptional regulation in mammalian germ cell development
Effects of Temporal Structure on Memory for Events
Autonomy, Collaboration and Job Satisfaction Among Gcrc Nurses
Absorption, Secretion, Malabsorption and Diarrhea
NeTS:Large:Collaborative Research: Network Innovation through Choice
Recently added grants:
Project 2: Current Good Manufacture Practices (CGMP) Production of Nucleoside-Modified mRNAs Encoding HIV-1 Envelopes
Animal Core
Core A Admin
Human mast cell and tissue acquisition core
Synthetic lethality screens in a nutrient sensitized Toxoplasma strain to identify novel proteins that mediate nutrient acquisition in chronic Toxoplasma infection.
Abstract
Funding Agency
Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Small Business Technology Transfer (STTR) Grants - Phase II (R42)
Project #
2R42HL053003-02
Application #
2029208
Study Section
Special Emphasis Panel (ZRG3-SSS-2 (02))
Project Start
1994-09-01
Project End
1998-08-31
Budget Start
1996-09-01
Budget End
1997-08-31
Support Year
2
Fiscal Year
1996
Total Cost
Indirect Cost
Institution
Name
Commonwealth Biotechnologies, Inc.
Department
Type
DUNS #
City
Richmond
State
VA
Country
United States
Zip Code
23235
Related projects
NIH 1997
R42 HL
Development of Heparin Antagonist for Clinical Use
Harris, Robert B. / Commonwealth Biotechnologies, Inc.
NIH 1996
R42 HL
Development of Heparin Antagonist for Clinical Use
Harris, Robert B. / Commonwealth Biotechnologies, Inc.
Comments
Be the first to comment on Robert Harris's grant